Regenerative medicine company Orthocell has announced plans to collaborate with DePuy Synthes Products, part of the Johnson & Johnson (J&J) family of companies, for its Ortho-ATI stem-cell approach.

The approach is meant for the regeneration of degenerate tendons and ligaments, and the collaboration has been facilitated by J&J.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Orthocell’s portfolio of products includes TGA-licensed autologous cell therapies, autologous tenocyte implantation (Ortho-ATI) and autologous chondrocyte implantation (Ortho-ACI).

Chronic treatment resistant tendon injuries that have a negative effect on the activities of patients’ daily living are treated using the new non-surgical approach Ortho-ATI.

"This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology."

Orthocell managing director Paul Anderson said: “This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology.”

See Also:

A collaborative study is planned to start in the first quarter of this year and will be a multi-centre trial conducted with Australia’s orthopaedic surgeon.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

University of Western Australia orthopaedic surgeon professor and the Shoulder and Elbow Society of Australia (SESA) president Allan Wang will lead the trial.

To date, several studies carried out by Orthocell found that Ortho-ATI is a durable, non-surgical solution for difficult-to-treat tendon injuries.

At present, it is available in Australia and New Zealand for patients who have failed conservative treatment options such as corticosteroid injections and exercise programmes, and who also have ongoing symptoms.